Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Yahoo! Finance
SAN CARLOS, Calif., May 20, 2022 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a late-stage biotechnology company developing novel T cell-based cancer immunotherapies, today announced that on May 19, 2022 (the “Date of Grant”), the Company approved the grant of inducement stock options covering an aggregate of 146,700 shares of Iovance’s common stock to 17 new non-executive employees. The awards were granted under Iovance’s 2021 Inducement Plan, which was adopted on September
Continue Reading